SASKATOON -- A Saskatoon man is going to the U.S. to see if he can take part in a clinical trial of the so-called liberation treatment for multiple sclerosis.
Andrew Dahlen is the first Saskatchewan resident to go to Albany, N.Y., for the final eligibility screening in a two-year, double-blind clinical trial.
"I'm certainly terrified for going but I'm more excited, so I'm not really too concerned about the risks," Dahlen said Thursday.
The province is putting up $2.2 million to have 86 Saskatchewan patients take part in the trial.
All prospective participants are first screened by a neurologist to ensure they meet eligibility requirements. A successful candidate must be a Saskatchewan resident, under the age of 60 and not had liberation treatment.
Candidates spend several days at Albany Medical Centre, where a final assessment determines whether they will be accepted.
The nature of the double-blind study means half of those participating will receive liberation therapy and half will get a placebo procedure.
With a population of about one million, Saskatchewan has some of the highest rates of MS in the country. About 3,500 Saskatchewan residents have MS.
-- The Canadian Press